Related Experiment Video

Updated: Apr 19, 2026

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.8K

The TLR4/NF-κB signaling pathway mediates the growth of colon cancer

H-Y Huang1, Z-J Zhang, C-B Cao

  • 1Suizhou Central Hospital, Suizhou Hospital Affiliated to Hubei Pharmaceutical College, Zengdu District, Suizhou, Hubei Province, China. qianjin7601@163.com.

European Review for Medical and Pharmacological Sciences
|January 4, 2015
PubMed
Abstract

Insights

The Toll-like receptor 4 (TLR4)/nuclear factor kappa B (NF-κB) pathway drives colon cancer growth and metastasis by increasing interleukin-6 and -8 production. Inhibiting TLR4 reduces NF-κB activation and tumor growth.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • The Toll-like receptor 4 (TLR4)/nuclear factor kappa B (NF-κB) signaling pathway plays a critical role in immune responses and inflammation.
  • Dysregulation of this pathway has been implicated in the development and progression of various cancers, including colon cancer.

Purpose of the Study:

  • To investigate the involvement of the TLR4/NF-κB pathway in colon cancer growth and metastasis.
  • To evaluate the therapeutic potential of inhibiting TLR4 in colon cancer.

Main Methods:

  • Analysis of TLR4 and NF-κB expression in human colon cancer specimens and adjacent normal tissues.
  • In vitro studies using the SW620 colon cancer cell line treated with a TLR4 inhibitor (CRX-526) and lipopolysaccharide (LPS).
  • In vivo studies using a nude mouse xenograft model of colon cancer treated with CRX-526.

Main Results:

  • Elevated mRNA and protein expression of TLR4 and NF-κB were observed in colon cancer tissues compared to normal tissues.
  • LPS stimulation increased TLR4, NF-κB expression, and production of IL-6 and IL-8 in SW620 cells, effects attenuated by CRX-526.
  • TLR4 inhibition with CRX-526 significantly reduced tumor size and TLR4/NF-κB expression in the mouse xenograft model.

Conclusions:

  • The TLR4/NF-κB signaling pathway is activated in colon cancer, contributing to tumor growth and metastasis through IL-6 and IL-8 production.
  • Inhibition of TLR4 effectively attenuates NF-κB activation and suppresses colon cancer growth.

More Related Videos

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer06:01

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer

Published on: July 6, 2017

10.1K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.9K

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.5K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K